Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 24;7(19):5925–5936. doi: 10.1182/bloodadvances.2022009652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 3. — Stroma-leukemia coculture increases toxicity mediated by JAK inhibitors. (A-B) Validating the effects of ruxolitinib (A) tofacitinib (B) from the HS-5 coculture screen (n = 81) in cocultures of CLL with primary MSCs (n = 3). t tests were used to compare the coculture mean with the reference value in monoculture. MSC1, MSC2, and MSC3 were derived from n = 3 different healthy donors. (C) STAT3 was phosphorylated in CLL cells from (n = 3) patient samples cocultured with HS-5 cells. STAT3 phosphorylation could be reversed by inhibition with ruxolitinib or tofacitinib. (D) STAT3 was phosphorylated in CLL cells from (n = 3) patient samples in the presence of conditioned medium derived from stromal cells. Ctrl, solvent control (DMSO); H, cocultures with HS-5 cells; M1-4, cocultures with MSC cells from (n = 4) different healthy donors; Ru, ruxolitinib (10 μM); To, tofacitinib (22.5 μM).